Engineered immune cells take on tough gynecologic tumors
NCT ID NCT05098171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called GC201 TIL for people with advanced gynecologic cancers that have not responded to standard therapies. Doctors take immune cells from the patient's own tumor, modify them to better fight cancer, and then infuse them back after a short chemotherapy. The goal is to see if this approach is safe and can shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GYNECOLOGIC TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Tenth People's Hospital
RECRUITINGShanghai, Shanghai Municipality, 200000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Patient's own immune cells fight advanced cancer?
- Can chemo and radiation steal fertility? a massive study aims to find out
- Cancer patients face more treatment side effects from rare lung infections
- ICU delirium drug study pulled before starting
- Tiny study compares trazodone and quetiapine for ICU delirium – but was cut short
- Which surgery is better for uterine septum? new trial aims to find out